Recombinant human erythropoietin therapy in end stage renal failure

A. J. Watson, J. L. Spivak

Research output: Contribution to journalReview articlepeer-review

Abstract

In summary, the initial studies of etythropoietin in anemic patients with end-stage renal disease are encouraging. Hopefully, larger, ongoing studies will provide answers to remaining questions such as blood pressure regulation, altered dialysis clearance, potential problems with arteriovenous access and the appropriate target hematocrit in these patients.

Original languageEnglish (US)
Pages (from-to)1086-1088
Number of pages3
JournalJournal of clinical pharmacology
Volume28
Issue number12
DOIs
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Recombinant human erythropoietin therapy in end stage renal failure'. Together they form a unique fingerprint.

Cite this